跳至主要内容
临床试验/JPRN-UMIN000007123
JPRN-UMIN000007123已完成2 期

A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy - ADOPT study

Hiroshima University Hospital Respiratory medicine0 个研究点目标入组 34 人开始时间: 2012年2月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Previously untreated with platinum doublet (2) transfusion or G-CSF within 2weeks prior to enrollment (3) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment (4) History of severe drug allergy (5) History of active double cancer within 5 years (6) History of active severe infections (7) Patients who have fever of over 38 degrees (8) Continuous administration of steroid drug (9) severe cardiac disease (10) History of thromboembolism or severe pulmonary disease (11) History of GI bleeding , ileus, GI ulceration (12) massive pleural or pericardial effusion, ascites (13) Symptomatic brain metastases (14) Uncontrollable hypertension or diabetes mellitus (15) Uncontrollable diarrhea (16) Wound of unrecovery (17) Traumatic fracture of unrecovery (18) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day) (19) History of pregnancy or lactation (20) Evaluated to be ineligible by a physician for other reasons

研究者

发起方
Hiroshima University Hospital Respiratory medicine

相似试验